Italy is 18th in Europe in terms of R&D spending, at 1.33% in relation to GDP (the target in the European Union is 3%), but even with few resources available, the value of our country's scientific production is at the top internationally. According to data from the Federation of Oncologists, Cardiologists and Hematologists, Italy, in fact, is responsible for 31% of the 2,169 studies authorized in Europe in 2022, and continues to be a leading player in clinical research on the Continent. There remains, however, the crucial issue of delays in access to new therapies. Today, too much time still elapses between authorization at the European level and reimbursability at the National level. In fact, it takes about 14 months (424 days), which is in line with the European average (432 days for EU-13+England) and better than France (527) and Spain (661), but significantly worse than Germany (126), which is the fastest in making new therapies available.